Abstract

The P2X7 receptor (P2X7R) is a ligand-gated plasma membrane ion channel belonging to the P2X receptor subfamily activated by extracellular nucleotides. General consensus holds that the physiological (and maybe the only) agonist is ATP. However, scattered evidence generated over the last several years suggests that ATP might not be the only agonist, especially at inflammatory sites. Solid data show that NAD+ covalently modifies the P2X7R of mouse T lymphocytes, thus lowering the ATP threshold for activation. Other structurally unrelated agents have been reported to activate the P2X7R via a poorly understood mechanism of action: (a) the antibiotic polymyxin B, possibly a positive allosteric P2X7R modulator, (b) the bactericidal peptide LL-37, (c) the amyloidogenic β peptide, and (d) serum amyloid A. Some agents, such as Alu-RNA, have been suggested to activate the P2X7R acting on the intracellular N- or C-terminal domains. Mode of P2X7R activation by these non-nucleotide ligands is as yet unknown; however, these observations raise the intriguing question of how these different non-nucleotide ligands may co-operate with ATP at inflammatory or tumor sites. New information obtained from the cloning and characterization of the P2X7R from exotic mammalian species (e.g., giant panda) and data from recent patch-clamp studies are strongly accelerating our understanding of P2X7R mode of operation, and may provide hints to the mechanism of activation of P2X7R by non-nucleotide ligands.

Highlights

  • The P2X7 receptor (P2X7R) belongs to the ionotropic P2X receptor subfamily (Burnstock, 2006)

  • In the original experiments by Bastien Gomperts the ATP Kd was measured in the absence of divalent cations (Ca2+ and Mg2+), it refers to the fully dissociated nucleotide species, and it is well known that threshold for P2X7R activation is lower

  • IL-1β release was not inhibited by treatment with apyrase, but enhanced. These findings suggest that serum amyloid A (SAA) does not induce ATP release, but rather directly interacts with the P2X7R

Read more

Summary

INTRODUCTION

The P2X7 receptor (P2X7R) belongs to the ionotropic P2X receptor subfamily (Burnstock, 2006). Given the large repertoire of nucleotide receptors with widely different affinity expressed by most cells, it is likely that even at tumor and inflammatory sites a variable response is generated in the presence of ATP concentrations that may range from the high nano to the low micromolar level. Several loss- or gain-of-function single-nucleotide polymorphisms (SNPs) have been described in the human P2X7 (Di Virgilio et al, 2017; Sluyter, 2017) Combination of these SNPs generates complex haplotypes that affect P2X7R functions, and make basically impossible to predict P2X7R activity on the basis of the mere identification of one SNP. Additional polymorphisms described in the P2X7 subunit and variably associated to disease susceptibility are: (a) rs17525809, causing replacement of a valine with an alanine (V76A), (b) rs28360447, causing replacement of a glycine with an arginine (G150R), (c) rs7958311, causing replacement of an arginine with an histidine (R270H), (d) rs28360457, that causes replacement of an arginine with glutamine (R307Q), (e) rs1718119, that causes replacement of an alanine with a threonine (A348T), (f) rs2230911, causing replacement of a threonine with a serine (T357S), (g) rs2230912, causing replacement of a glutamine with an arginine (Q460R), (h) rs2230913, causing replacement of a histidine with a glutamine (H521Q), and (i) rs1653624, causing replacement of an isoleucine with an asparagine (I568N) (Wiley et al, 2011; Table 1)

Amino acid substitution
Loss Loss Gain Loss Loss Gain Loss Loss Loss Neutral Loss
EXTRACELLULAR ATP MIGHT NOT BE THE ONLY AGONIST
CONCLUSION
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call